The ASAP3 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line. The product is generated through targeted disruption of the ASAP3 gene, which encodes an Arf GTPase-activating protein. This knockout model provides a loss-of-function tool for investigating ASAP3 functions in cancer biology. As a polyclonal population, these cells maintain genetic diversity while effectively abrogating ASAP3 protein expression, enabling robust functional studies without clonal isolation.
The parental A-549 cell line is an established human alveolar basal epithelial model derived from a lung carcinoma of a 58-year-old male. These adherent epithelial cells exhibit an alveolar type II pneumocyte phenotype and are widely used in respiratory research, lung cancer biology, and drug metabolism studies. A-549 cells provide a classic in vitro system for examining adenocarcinoma pathogenesis and therapeutic responses. The ASAP3 knockout in this well-characterized background facilitates direct gene function interrogation in a clinically relevant lung cancer context.
ASAP3 functions as a negative regulator of Arf GTPases, including Arf1 and Arf6, modulating vesicular trafficking and actin cytoskeleton dynamics. The protein localizes to focal adhesions and interacts with paxillin and cortactin, linking integrin adhesion signals to actin remodeling. Downstream targets include PIP5K, Rac1, and FAK, which coordinate actin polymerization and focal adhesion turnover. Upstream activation occurs via growth factor receptors and integrin engagement. Thus, ASAP3 sits at the intersection of cell adhesion and migration pathways, and its disruption is expected to impair cytoskeletal reorganization.
In A-549 lung adenocarcinoma cells, ASAP3 regulates focal adhesion dynamics and cell migration, processes critical for tumor invasiveness. Knockout of ASAP3 is anticipated to reduce focal adhesion disassembly and slow cell motility, potentially attenuating metastatic potential. This polyclonal knockout cell population therefore provides a valuable system for dissecting lung cancer progression mechanisms. By comparing parental and knockout cells, researchers can assess ASAP3’s contribution to cytoskeletal remodeling and adhesion pathways, aiding in the identification of novel therapeutic targets.
These ASAP3 knockout A-549 polyclonal cells are suited for cancer cell migration and invasion assays, Arf signaling pathway studies, drug target validation, and functional genomics. Standard techniques include western blotting, RT-qPCR, immunofluorescence, and cell adhesion assays. Functional consequences can be evaluated using wound healing and transwell invasion assays, while RNA-seq enables transcriptomic profiling. This versatile model supports research into the role of ASAP3 in lung adenocarcinoma and related malignancies. For further details, please contact Ascent Research.
